Nucleoside-modified mRNA-LNP vaccines are a versatile platform noted for eliciting both humoral and cellular immune responses. Building on that platform, the investigators developed an mRNA-LNP vaccine targeting Hepatitis C virus (HCV) and intentionally optimized the construct by including the nonstructural HCV viroporin p7. The rationale for adding p7 was to improve HCV-like particle secretion and thereby enhance the humoral immune response beyond what is achieved by presenting antigenic epitopes alone.
The study compared two constructs: a non-optimized mRNA-LNP antigen construct and an optimized construct that incorporates p7. The primary aims were to measure antigen-specific cellular immunity (CD4+ and CD8+ T cell responses, and T follicular helper cells) and to assess the magnitude and functionality of antibody responses, including neutralizing activity and reactivity against heterologous viral strains.
Immune responses were measured in immunized mice. The authors used established cellular and serologic assays to quantify antigen-specific T cell responses, T follicular helper cell responses linked to antibody production, binding antibody titers, and neutralization capacity. Details on dosing, immunization schedule, or specific assay platforms were not reported in the PubMed abstract and thus are not available from the source.
Both the non-optimized and the p7-optimized mRNA-LNP constructs elicited antigen-specific functional CD4+ and CD8+ T cell responses in mice. In addition, both constructs induced T follicular helper (Tfh) cell responses, which are mechanistically associated with generation and maturation of antibody responses. These cellular outcomes are consistent with prior observations that the mRNA-LNP platform stimulates coordinated cellular and humoral immunity.
Compared with the non-optimized construct, the optimized mRNA-LNP vaccine that included p7 produced superior binding and neutralizing antibody responses in immunized mice. The optimized construct improved HCV-like particle secretion and this structural or assembly advantage correlated with an enhanced humoral profile. The abstract reports stronger functional antibody responses after immunization with the optimized vaccine but does not provide numerical titers, statistical values, or detailed assay conditions in the source text.
A notable finding reported in the abstract is that the optimized p7-containing construct elicited stronger humoral responses against heterologous viral strains compared to the non-optimized construct. This suggests improved breadth of antibody recognition, which is an important attribute for vaccines against genetically diverse viruses such as HCV. Specific heterologous strains tested, neutralization breadth metrics, and quantitative results were not detailed in the abstract and therefore are not reported here.
The results support the concept that optimizing mRNA-LNP vaccine design by including viral elements that facilitate particle formation or augment antigen presentation can improve humoral immunogenicity. For HCV, enhancement of HCV-like particle secretion via inclusion of p7 appears to increase both binding and neutralizing antibody responses in a mouse model. The authors emphasize that translating these preclinical findings into humans will require additional investigation, including further preclinical validation and human clinical studies to confirm safety, immunogenicity, and protective efficacy.
Overall, this study demonstrates the potential to extend the utility of the mRNA-LNP platform for HCV by incorporating nonstructural viral components with functional roles in particle biology and immunity.
The authors disclosed funding and relationships relevant to the work. Financial support reported in the abstract includes National Institute of Allergy and Infectious Diseases and other NIH funding. Several authors declared relationships with biotech companies and listed patents: specific patents and corporate relationships are reported by the authors in the source. Where detailed patent numbers, company names, or the full scope of financial relationships were provided in the original article abstract or conflict-of-interest statement, they are summarized here; the abstract reports multiple patents and equity or board relationships for some investigators. These disclosures should be consulted in the full text for precise details.
Note: Numerical data, detailed experimental methods, immunization regimens, and full statistical analyses were not provided in the PubMed abstract and therefore are not included in this summary. The source indicates the study was published in Vaccine (2026) and is available as a free article; consult the full text for complete methodological and quantitative information.